The time has come: sparing injectables in paediatric MDR-TB

The Lancet Respiratory Medicine

Volumn 5, Issue 4, 2017, Pages 245-246

  Weld, Ethel D ^a   Garcia Prats, Anthony J ^b   Furin, Jennifer J ^c   Bailey, Theodore C ^d   Hesseling, Anneke C ^b   Dooley, Kelly E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CAPREOMYCIN; CLOFAZIMINE; DELAMANID; ISONIAZID; KANAMYCIN; LINEZOLID; RIFAMPICIN;

BACTERIAL LOAD; CHILD; CLINICAL PRACTICE; DRUG MONITORING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEARING IMPAIRMENT; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; NOTE;

EID: 85016110628     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30078-4     Document Type: Note

References (15)

1. 1 Huth, ME, Ricci, AJ, Cheng, AG, Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol, 2011, 2011, 937861.
2. 2 Beaubien, AR, Ormsby, E, Bayne, A, et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother 35 (1991), 1070–1074.
3. 3 Tran Ba Huy, P, Bernard, P, Schacht, J, Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 77 (1986), 1492–1500.
4. 4 Modongo, C, Pasipanodya, JG, Zetola, NM, Williams, SM, Sirugo, G, Gumbo, T, Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother 59 (2015), 6337–6343.
5. 5 Seddon, JA, Hesseling, AC, Godfrey-Faussett, P, Schaaf, HS, High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 69 (2014), 458–464.
6. 6 Franck, C, Seddon, JA, Hesseling, AC, Schaaf, HS, Skinner, D, Reynolds, L, Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. BMC Infect Dis, 14, 2014, 426.
7. 7 Donald, PR, Sirgel, FA, Venter, A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 5 (2001), 533–538.
8. 8 Ahuja, SD, Ashkin, D, Avendano, M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med, 9, 2012, e1001300.
9. 9 Falzon, D, Gandhi, N, Migliori, GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42 (2013), 156–168.
10. 10 WHO. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update, 2016, World Health Organization, Geneva.
11. 11 Gler, MT, Skripconoka, V, Sanchez-Garavito, E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366 (2012), 2151–2160.
12. 12 Matsumoto, M, Hashizume, H, Tomishige, T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 3, 2006, e466.
13. 13 Diacon, AH, Dawson, R, Hanekom, M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15 (2011), 949–954.
14. 14 Hafkin J FM, Hesseling A, Garcia-Prats AJ, et al. Pharmacokinetics and safety of delamanid in paediatric MDR-TB patients, ages 6–17 years. International Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA, USA; Sept 18–21, 2015.
15. 15 Powers, M, Faden, R, Social justice: the moral foundations of public health and heath policy, 2006, Oxford University Press, Oxford.